Total Funding
67
57
Total FundingGrant raised
Growth Score 67 in past quarter
-4 pts
Heat Score 57 in past quarter
1 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
63295
Hemetron offers a handheld blood testing device that measures biomarkers for at‑home health monitoring and remote result sharing.
- Alexander Tanno: CEO
About the Company
Over 100 million people globally suffer from Inflammatory Rheumatic Diseases (IRD), causing chronic pain, fatigue, and flare-ups that significantly reduce quality of life. Traditional monitoring, with doctor visits every 3-6 months, leaves gaps in tracking disease progression, leading to poor outcomes and suffering. Hemetron AG addresses this
problem with a groundbreaking remote monitoring system, enabling patients to conduct at-home blood tests. Results are digitally sent to physicians for timely treatment adjustments. This solution improves disease tracking, patient engagement, and reduces costs. We revolutionize chronic patient care through more personalized and effective treatments, delivering better outcomes at lower costs.